Wall Street analyst estimates for IGC Pharma, Inc. (IGC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-05 | $-0.02 | ||
| 2026-11-13 | $-0.02 | ||
| 2026-08-14 | $-0.03 | $-0.02 | -50.0% |
| 2026-05-15 | $-0.02 | $-0.02 | +0.0% |
| 2026-03-20 | $-0.02 | $-0.02 | +0.0% |
| 2025-11-14 | $-0.02 | $-0.02 | +0.0% |
| 2025-08-19 | $-0.02 | $-0.03 | +20.0% |
| 2025-06-30 | $-0.02 | $-0.02 | +0.0% |
Valuation Ratios
| Price / Book | 4.20 |
| EV / EBITDA | -3.89 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $580372 | $2.2M | $5.1M | $4.1M | $898000 | $397000 | $911000 | $1.3M | $1.3M | $1.2M |
| Cost of Revenue | $362135 | $2.1M | $5.0M | $4.0M | $1.2M | $203000 | $1.1M | $612000 | $652000 | $834000 |
| Gross Profit | $218237 | $81524 | $132000 | $115000 | -$349000 | $194000 | -$158000 | $733000 | $619000 | $352000 |
| Research & Development | $114000 | $137000 | $1.3M | $1.0M | $929000 | $2.3M | $3.5M | $3.8M | $3.7M | $5.2M |
| Selling, General & Admin | $2.3M | $1.9M | $3.5M | $6.0M | $7.4M | $13.3M | $8.0M | $6.8M | $4.4M | $5.4M |
| Operating Expenses | $2.3M | $1.9M | $4.8M | $7.0M | $8.4M | $15.6M | $11.4M | $10.5M | $8.1M | $10.6M |
| Operating Income | -$2.1M | -$1.8M | -$4.6M | -$6.9M | -$8.7M | -$15.4M | -$11.6M | -$9.8M | -$7.4M | -$10.2M |
| EBITDA | -$1.2M | -$1.7M | -$4.6M | -$6.7M | -$8.3M | -$14.4M | -$10.8M | -$12.4M | -$6.7M | -$6.2M |
| Interest Expense | $223464 | $30742 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.8M | -$1.8M | -$4.1M | -$7.3M | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M | -$6.5M |
| Income Tax | $14431 | $464 | $2000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.9M | -$1.8M | -$4.1M | -$7.3M | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M | -$6.5M |
| EPS | $-0.07 | $-0.06 | $-0.12 | $-0.19 | $-0.21 | $-0.30 | $-0.22 | $-0.22 | $-0.09 | $-0.07 |
| EPS (Diluted) | $-0.07 | $-0.06 | $-0.12 | $-0.19 | $-0.21 | $-0.30 | $-0.22 | $-0.22 | $-0.09 | $-0.07 |
| Shares Outstanding (Diluted) | $25.7M | $27.9M | $35.4M | $39.5M | $42.0M | $50.0M | $52.6M | $58.8M | $76.5M | $95.0M |
Price
| Price | $0.27 |
| Market Cap | $27M |
| Exchange | AMEX |
| Country | US |
Related companies: ANTX · BOLD · INTS · ITRM · NTRB · NXTC · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IGC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks